About
Clinically active Physician Immunologist with a demonstrated history of working in the…
Activity
-
I'm thrilled to be part of this event on gamma delta cells! Looking forward to insightful discussions and collaborations. Join us this Monday!
I'm thrilled to be part of this event on gamma delta cells! Looking forward to insightful discussions and collaborations. Join us this Monday!
Liked by John Maher
-
These are exciting news. After a long hiatus, Lipomedix is back on track with a new clinical batch of Promitil.
These are exciting news. After a long hiatus, Lipomedix is back on track with a new clinical batch of Promitil.
Liked by John Maher
Experience & Education
-
Freelance
View John’s full experience
See their title, tenure and more.
or
Licenses & Certifications
Publications
-
CAR-T cell technologies that interact with the tumour microenvironment in solid tumours
Expert Review of Clinical Immunology
-
Intratumoral pan-ErbB targeted CAR-T for head and neck squamous cell carcinoma: interim analysis of the T4 immunotherapy study.
Journal for Immunotherapy of Cancer
-
Solid tumours: Building bridges to CAR-T success
Clinical and Translational Discovery
-
CAR T cell immunotherapy of epithelial ovarian cancer: past, present and a view of the horizon
Cell and Gene Therapy Insights
-
Highly effective liquid and solid phase extraction methods to concentrate radioiodine isotopes for radioiodination chemistry.
Journal of Labelled Compounds and Radiopharmaceuticals
-
TGF-beta 1 potentiates gamma delta T-cell adoptive immunotherapy of cancer.
Cell Reports Medicine
-
Prospects for Development of Induced Pluripotent Stem Cell‐Derived CAR‐Targeted Immunotherapies.
Archivum Immunologiae et Therapiae Experimentalis
-
Approaches for refining and furthering the development of CAR-based T cell therapies for solid malignancies.
Expert Opinion in Drug Discovery
-
How can we engineer CAR T cells to overcome resistance?
Biologics: Targets and Therapy
-
Efficient ex vivo expansion of gd T-cells from AML patients requires elimination of circulating leukemia blasts.
Advances in Leukemia Treatment and Research
-
Lymphodepletion strategies to potentiate adoptive T-cell immunotherapy – what are we doing; where are we going?
Expert Opinion in Biological Therapy
-
PanErbB-targeted CAR T-cell immunotherapy of head and neck cancer.
Expert Opinion in Biological Therapy
-
Engineering of chimeric natural killer receptors to develop precision adoptive immunotherapies for cancer.
Clinical and Experimental Immunology
-
CAR T-cell immunotherapy of B-cell malignancy: the story so far.
Therapeutic Advances in Vaccines and Immunotherapy.
-
Pancreatic Cancer UK Grand Challenge: Developments and challenges for effectiveCAR T cell therapy for pancreatic ductal adenocarcinoma.
Pancreatology
-
Novel approaches to promote CAR T cell function in solid tumors.
Expert Opinion on Biological Therapy
-
Synergistic combination of oncolytic virotherapy with CAR T-cell therapy (book chapter).
Progress in Molecular Biology and Translational Science
-
Strategies to address chimeric antigen receptor tonic signaling.
Molecular Cancer Therapeutics. 17(9):1795-1815.
-
A dual reporter iodinated labeling reagent for cancer positron emission tomography imaging and fluorescence-guided Surgery.
Journal of Medicinal Chemistry. 61(4):1636-1645.
-
Clinically compliant spatial and temporal imaging of Chimeric Antigen Receptor T-cells.
Nature Communications. 9(1):1081.
-
Perspectives on Chimeric Antigen Receptor T-cell immunotherapy for solid tumors.
Frontiers in Immunology. 9:1104
-
Preclinical development of chimeric antigen receptor T-cell immunotherapy: implications of design for efficacy and safety.
Best Practice & Research Clinical Haematology. 31(2) 117-125.
-
Prospects for combined use of oncolytic viruses and CAR T-cells.
Journal for Immunotherapy of Cancer. 5(1):90.
-
Cancer Immunotherapy: Whence and Whither.
Molecular Cancer Research. PJ Stambrook, J Maher, F Farzaneh
-
Generation of human islet-specific regulatory T cells by TCR gene transfer.
Journal of Autoimmunity
-
Prospects for combined use of oncolytic viruses and CAR T-cells.
Journal of Immunotherapy of Cancer
-
Targeting of aberrant αvβ6 integrin expression in solid tumors using chimeric antigen receptor-engineered T-cells.
Molecular Therapy 25(1):259-273.
-
Expression of a chimeric antigen receptor specific for donor HLA class I enhances the potency of human regulatory T cells in preventing human skin transplant rejection.
American Journal of Transplantation. In Press. doi: 10.1111/ajt.14185
-
In vitro potency, in vitro and in vivo efficacy of liposomal alendronate in combination with gd T-cell immunotherapy in mice.
Journal of Controlled Release 241:229-241.
-
The mucin MUC1 modulates the tumor immunological microenvironment through engagement of the lectin Siglec-9.
Nature Immunology. 17(11):1273-1281.
-
Gated chimeric antigen receptor T-cells: the next logical step in reducing toxicity.
Translational Cancer Research 5(suppl 1): S61-S65
-
Role of the colony-stimulating factor (CSF)/ CSF-1 receptor axis in cancer.
Biochemical Society Transactions Apr 15;44(2):333-41.
-
The role of the Met/ HGF axis in malignant mesothelioma.
Biochemical Society Transactions Apr 15;44(2):363-70.
-
Antigen specificity using chimeric antigen receptors: the future of regulatory T-cell therapy.
Biochemical Society Transactions Apr 15;44(2):342-8.
-
Targeting of tumor-associated glycoforms of MUC1 with CAR T cells.
Immunity 45:945-946
-
The integrin avb6: a novel target for CAR T-cell immunotherapy.
Biochemical Society Transactions Apr 15;44(2):349-55
-
How should a District General Hospital immunology service screen for antinuclear antibodies? An “in the field” audit.
Clinical and Experimental Immunology 180(1):52-7
-
ErbB-targeted CAR T-cell immunotherapy of cancer.
Immunotherapy 7(3):229-41.
-
Adoptive Immunotherapy of Cancer Using Chimeric Antigen Receptor–Engineered T Cells.
Forum on Immunopathological Diseases and Therapeutics 5(1-2): 47-67.
-
CAR T-cell immunotherapy: the path from the by-road to the freeway?
Molecular Oncology 9(10):1994-2018.
-
Chimeric antigen receptors: On the road to realising their full potential.
World Journal of Immunology 5(3):86-94.
-
Clinical evaluation of ErbB-targeted CAR T-cells following intra-cavitary delivery in patients with ErbB-expressing solid tumors.
Methods in Molecular Biology 1317:365-82.
-
Ovarian Cancer immunotherapy using PD-L1 siRNA targeted delivery from folic acid-functionalized polyethyleimine: Strategies to enhanced T cell killing.
Advanced Healthcare Materials 4(8):1180-9.
-
Prospects for adoptive immunotherapy of pancreatic cancer using chimeric antigen receptor-engineered T-cells.
Immunopharmacology and Immunotoxicology
-
Adoptive immunotherapy of epithelial ovarian cancer with Vγ9Vδ2 T-cells, potentiated by liposomal alendronic acid.
Journal of Immunology 193(11):5557-5566.
-
Cryoglobulinemia identified by repeated analytical failure of laboratory tests.
The Lancet 383(9914):382.
-
Use of Immunoglobulin Replacement Therapy in the Management of Primary Immunodeficiency Disorders.
The Foundation Years Journal 8(4): 18-25.
-
Use of retroviral-mediated gene transfer to deliver and test function of chimeric antigen receptors in human T-cells.
Journal of Biological Methods 1(2): e7
-
Anti-tumor immunity – easy as 1 2 3 with monoclonal bispecific trifunctional antibodies?
Cancer Research. 73(18): 1–5.
-
Design of a phase 1 clinical trial to evaluate intra-tumoral delivery of ErbB-targeted CAR T-cells in locally advanced or recurrent head and neck cancer.
Human Gene Therapy Clinical Development. 24(3):134-142.
-
Pre-clinical in-vivo modeling of cytokine release syndrome induced by ErbB re-targeted human T-cells – identifying a window of therapeutic opportunity?
Journal of Immunology. 191(9):4589-98.
-
Synergistic chemo-immunotherapy of epithelial ovarian cancer using ErbB re-targeted T-cells combined with carboplatin.
Journal of Immunology. 191(5):2437-45.
-
The role of the clinical immunology laboratory in disease monitoring.
World Journal of Immunology. 3(2) 18-30.
-
Use of gene-modified regulatory T-cells to control autoimmune and alloimmune pathology: is now the right time?
Clinical Immunology. 150(1):51-63.
-
Whole body imaging of adoptively transferred T cells using MRI, SPECT and PET techniques, with a focus on regulatory T cells.
Clinical and Experimental Immunology. 172: 169-77.
-
Dual targeting of ErbB2 and MUC1 in breast cancer using chimeric antigen receptors engineered to provide complementary signaling.
Journal of Clinical Immunology. 32(5): 1059-1070.
-
Flexible targeting of ErbB dimers that drive tumorigenesis using genetically engineered T-cells.
Molecular Medicine. 18(1): 565-76
-
Immunotherapy of malignant disease using chimeric antigen receptor-engrafted T-cells.
ISRN Oncology. 2012: 278093.
-
Transforming growth factor-β1 is constitutively secreted by Chinese Hamster Ovary cells and is functional in human cells.
Biotechnology and Bioengineering. 108(11):2759-6.
-
Trafficking of CAR-engineered human T-cells following regional or systemic adoptive transfer in SCID Beige mice.
Journal of Clinical Immunology. 31: 710-8.
-
Book Review: Applied and Experimental Immunotherapy.
British Journal of Clinical Pharmacology. 72: 524.
-
Infective endocarditis: how immunology tests may help or mislead.
The Foundation Years Journal. 5(2): 57-61.
-
Selective expansion of chimeric antigen receptor-targeted T-cells with potent effector function using interleukin-4.
Journal of Biological Chemistry. 285: 25538-44.
-
Adoptive T-Cell Immunotherapy of Cancer using Chimeric Antigen Receptor-Grafted T-cells.
Archivum Immunologiae et Therapiae Experimentalis. 58: 165-78
-
Vitamin D deficiency - the commonest secondary immunodeficiency disorder?
British Medical Journal
-
CAR mechanics: driving T cells into the MUC of cancer.
Cancer Research 69: 4559-62
-
An audit of serological screening for coeliac disease: real life may not quite mirror research?
The Foundation Years Journal 3: 27-29.
-
Re-targeting of human T-cells to tumour-associated MUC1 – the evolution of a chimeric antigen receptor.
Journal of Immunology 180: 4901-9.
-
Harnessing the tumour-derived cytokine, colony-stimulating factor-1, to co-stimulate T-cell growth and activation.
Molecular Immunology 45: 1276-87.
-
Modulation of dendritic cell differentiation by colony-stimulating factor-1: role of phosphatidylinositol 3'-kinase and delayed caspase activation.
Journal of Leukocyte Biology 82: 1446-54.
-
Dermatofibrosarcoma protuberans in a patient with X-linked agammaglobulinaemia.
Journal of Clinical Pathology. 60: 1162-1164.
-
Increase in allergy following donor lymphocyte infusions.
Bone Marrow Transplantation 37: 983-4.
-
Targeting cytotoxic T-lymphocytes for cancer immunotherapy.
British Journal of Cancer 91, 817-821.
-
Application of artificial T cell receptor technology to cancer immunotherapy
CPD Bulletin Immunology & Allergy (UK) 2: 89-91.
-
Human T lymphocyte cytotoxicity and proliferation directed by a single chimeric TCR/ CD28 receptor.
Nature Biotechnology 20: 70-75.
-
Evidence for cell-type specific differences in transformation by N-, H- and K-ras.
Oncogene 11: 1639-1647.
-
Evidence that Ras and Myc mediate the synergy between SCF and M-CSF with GM-CSF and IL-3.
Leukemia 8: 1970-1981.
-
Retroviral-mediated gene transfer of a mutant H-ras gene into normal bone marrow alters myeloid cell proliferation and differentiation.
Experimental Hematology 22: 8-12.
-
A circadian distribution to febrile episodes in neutropenic patients.
Supportive Care in Cancer
-
Plantar power - the clinical usefulness and reliability of the plantar reflex.
British Medical Journal
-
The eIF4A inhibitor silvestrol sensitizes T-47D ductal breast carcinoma cells to external-beam radiotherapy.
Clinical and Translational Radiation Oncology
Patents
-
Gamma delta T-cell expansion method
Issued EU EP3227435A1
See patentMethod to expand gamma delta T-cells from peripheral blood
-
Nucleic Acids Encoding Chimeric T Cell Receptors.
Issued US 7446190 B2
CD28 + CD3z second generation chimeric antigen receptor and its enablement in primary human T-cells
Other inventors -
Honors & Awards
-
Chair (2016-2021)
Scientific Advisory Committee Worldwide Cancer Research
-
Member (2015-2016)
Tissue Bank Advisory Council Breast Cancer Now
2015-2016
-
Deputy Chair (2015-2017)
Scientific Advisory Board Breast Cancer Now
2015-2017
More activity by John
-
We're thrilled to announce the signing of a five-year Master Services Agreement with a prominent U.S. NCI-designated cancer center for their GMP…
We're thrilled to announce the signing of a five-year Master Services Agreement with a prominent U.S. NCI-designated cancer center for their GMP…
Liked by John Maher
-
🚀 Unlock Creative Financing with AI + Automation! 🚀 Struggling to find cash-flowing deals with high interest rates and limited inventory? Creative…
🚀 Unlock Creative Financing with AI + Automation! 🚀 Struggling to find cash-flowing deals with high interest rates and limited inventory? Creative…
Liked by John Maher
-
🚀 Exciting News! Our Creative Community is Now Open! 🚀 We’re beyond thrilled to announce the launch of our Creative Community - the first-ever…
🚀 Exciting News! Our Creative Community is Now Open! 🚀 We’re beyond thrilled to announce the launch of our Creative Community - the first-ever…
Liked by John Maher
-
📄🙏 We are grateful for the reception of our latest publication in Nature Communications (Nature Portfolio) 💉 In this study, we investigate how CAR…
📄🙏 We are grateful for the reception of our latest publication in Nature Communications (Nature Portfolio) 💉 In this study, we investigate how CAR…
Liked by John Maher
-
Very glad to share our thoughts at Leucid on how CAR-T engages with the solid tumour microenvironment. https://lnkd.in/g3y2Xtzy
Very glad to share our thoughts at Leucid on how CAR-T engages with the solid tumour microenvironment. https://lnkd.in/g3y2Xtzy
Posted by John Maher
-
✨ Excited to share my recent interview where I discuss my career journey from Academia to Industry, my motivation for the career trajectory change…
✨ Excited to share my recent interview where I discuss my career journey from Academia to Industry, my motivation for the career trajectory change…
Liked by John Maher
-
My wife just told me she's got no magnesium in her body. I said 0mg. I'm recruiting for recruitment businesses in the Life Sciences sector…
My wife just told me she's got no magnesium in her body. I said 0mg. I'm recruiting for recruitment businesses in the Life Sciences sector…
Liked by John Maher
-
TOUR: Tranforming cancer OUtcomes through Research is rebranding! We were nominated in the Research Category of King's College London Faculty of Life…
TOUR: Tranforming cancer OUtcomes through Research is rebranding! We were nominated in the Research Category of King's College London Faculty of Life…
Liked by John Maher
-
✨ BIG NEWS: Our creative finance tool is now LIVE!!! 🔮 TLDR; We've been working tirelessly to bring this new product to our users. For a while now,…
✨ BIG NEWS: Our creative finance tool is now LIVE!!! 🔮 TLDR; We've been working tirelessly to bring this new product to our users. For a while now,…
Liked by John Maher
-
We are delighted to announce that Emily Sullivan has progressed to a Senior Associate Trade Mark Attorney and Alex Cavell, Dr. Anja Koller, Juliana…
We are delighted to announce that Emily Sullivan has progressed to a Senior Associate Trade Mark Attorney and Alex Cavell, Dr. Anja Koller, Juliana…
Liked by John Maher
-
International LIT Symposium “Synthetic Immunology / Synthetic Biology” in Regensburg: More than 150 leading scientists from around the world…
International LIT Symposium “Synthetic Immunology / Synthetic Biology” in Regensburg: More than 150 leading scientists from around the world…
Liked by John Maher
-
Don't forget to sign up for this Wednesday's webinar: Innovative Strategies for Improving Potency of Allogeneic γδ T Cells. Most approved CAR-T…
Don't forget to sign up for this Wednesday's webinar: Innovative Strategies for Improving Potency of Allogeneic γδ T Cells. Most approved CAR-T…
Liked by John Maher
-
Excited to share my recent talk with the Orlando REI Local on a topic near and dear to me: Automating Deal Finding & Analysis in Real Estate! We…
Excited to share my recent talk with the Orlando REI Local on a topic near and dear to me: Automating Deal Finding & Analysis in Real Estate! We…
Liked by John Maher
Other similar profiles
Explore collaborative articles
We’re unlocking community knowledge in a new way. Experts add insights directly into each article, started with the help of AI.
Explore MoreOthers named John Maher in United Kingdom
-
John Maher
Director at Further Education Partnership (FEP)
-
John Maher
Deputy Managing Director at The Rosebery Group
-
John Maher
-
John Maher
Implementation Director at Landytech
109 others named John Maher in United Kingdom are on LinkedIn
See others named John Maher